Multiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunities - PubMed
3 hours ago
- #therapeutic biomarkers
- #multiomic analysis
- #small cell lung cancer
- Multiomic characterization of small cell lung cancer (SCLC) reveals distinct subtypes based on lineage-related transcription factors (TFs): ASCL1 (SCLC-A), NEUROD1 (SCLC-N), POU2F3 (SCLC-P), and YAP1 (SCLC-Y).
- A large-scale analysis of 944 patient samples identified SCLC-A as the most common subtype (25.6%), followed by mixed (27.9%), TF- (19.5%), SCLC-Y (12.5%), SCLC-N (10.2%), and SCLC-P (4.3%).
- The SCLC-Y subtype showed the highest expression of immune-related gene signatures, including T-cell inflamed, natural killer cell, and Stimulator of Interferon Genes pathways.
- Mixed samples expressing YAP1 also exhibited comparable immune-related gene signatures to SCLC-Y.
- Clinically relevant target genes like DLL3, SEZ6, and BCL2 (in SCLC-A) and SSTR2 (in SCLC-N) were increased in mixed samples expressing ASCL1 and NEUROD1.
- The TF- subtype lacked associations with immune-related signatures or other target genes.
- Findings highlight molecular heterogeneity in SCLC and potential biomarkers for targeted therapies.